deltatrials
Completed PHASE2 INTERVENTIONAL 2-arm NCT04189588

Phase 2 Study IV QUZYTTIR™ (Cetirizine Hydrochloride Injection) vs V Diphenhydramine (versus)

A Phase 2 Exploratory Study of Intravenous QUZYTTIR™ (Cetirizine Hydrochloride Injection) Versus Intravenous Diphenhydramine in the Prevention of Hypersensitivity Infusion Reactions

Sponsor: TerSera Therapeutics LLC

Conditions Oncology Patients Receiving Chemotherapy
Interventions Cetirizine HCl 10 mg/mL Diphenhydramine 50 mg/mL anti-CD20 such as Rituximab or Paclitaxel
Updated 13 times since 2020 Last updated: Oct 4, 2023 Started: Mar 25, 2020 Primary completion: Nov 23, 2020 Completion: Dec 23, 2020
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A PHASE2 clinical study on Oncology Patients Receiving Chemotherapy, this trial is completed. The trial is conducted by TerSera Therapeutics LLC and has accumulated 13 data snapshots since 2020. Oncology trials at this stage typically focus on safety, tolerability, and early efficacy signals.

Status Flow

~Jan 2020 – ~Apr 2020 · 3 months · monthly snapshot~Apr 2020 – ~Jul 2020 · 3 months · monthly snapshot~Jul 2020 – ~Aug 2020 · 31 days · monthly snapshot~Aug 2020 – ~Sep 2020 · 31 days · monthly snapshot~Sep 2020 – ~Oct 2020 · 30 days · monthly snapshot~Oct 2020 – ~Dec 2020 · 2 months · monthly snapshot~Dec 2020 – ~Jan 2021 · 31 days · monthly snapshot~Jan 2021 – ~Mar 2021 · 59 days · monthly snapshot~Mar 2021 – ~Jun 2022 · 15 months · monthly snapshot~Jun 2022 – ~Nov 2023 · 17 months · monthly snapshot~Nov 2023 – ~Jul 2024 · 8 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – present · 22 months · monthly snapshot

Change History

13 versions recorded

  1. Sep 2024 — Present [monthly]

    Completed PHASE2

  2. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE2

  3. Nov 2023 — Jul 2024 [monthly]

    Completed PHASE2

  4. Jun 2022 — Nov 2023 [monthly]

    Completed PHASE2

  5. Mar 2021 — Jun 2022 [monthly]

    Completed PHASE2

    Status: Active Not Recruiting → Completed

▶ Show 8 earlier versions

  1. Jan 2021 — Mar 2021 [monthly]

    Active Not Recruiting PHASE2

    Status: Recruiting → Active Not Recruiting

  2. Dec 2020 — Jan 2021 [monthly]

    Recruiting PHASE2

  3. Oct 2020 — Dec 2020 [monthly]

    Recruiting PHASE2

  4. Sep 2020 — Oct 2020 [monthly]

    Recruiting PHASE2

  5. Aug 2020 — Sep 2020 [monthly]

    Recruiting PHASE2

  6. Jul 2020 — Aug 2020 [monthly]

    Recruiting PHASE2

  7. Apr 2020 — Jul 2020 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  8. Jan 2020 — Apr 2020 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • TerSera Therapeutics LLC
Data source: TerSera Therapeutics LLC

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations